Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)

Overview of attention for article published in Journal of Thrombosis & Haemostasis, November 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 1 news outlet
twitter: 3 X users

patent: 1 patent

Readers on

mendeley: 35 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 11,943 followers.

RT @JTHjournal: New article: Klamroth et al @Vivantes investigate feasibility of subcutaneous fVIII (turoctocog alfa pegol) administration…

New article: Klamroth et al @Vivantes investigate feasibility of subcutaneous fVIII (turoctocog alfa pegol) administration to reduce treatment burden of #hemophilia A. The development was stopped due to immogenicity. https://t.co/OQUKFY9O14 #blooducati…

@ProfMakris The publication is now available: Pharmacokinetics, immunogenicity, safety and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1): https://t.co/z9UJGx1GpN

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.